HOOKIPA Pharma (HOOK)
(Delayed Data from NSDQ)
$0.90 USD
-0.02 (-1.86%)
Updated Aug 6, 2025 04:00 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HOOK 0.90 -0.02(-1.86%)
Will HOOK be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for HOOK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HOOK
Wall Street Analysts Think HOOKIPA Pharma (HOOK) Could Surge 622.75%: Read This Before Placing a Bet
Generation Bio Co. (GBIO) Reports Q2 Loss, Tops Revenue Estimates
HOOK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe HOOKIPA Pharma (HOOK) Could Rally 634.38%: Here's is How to Trade
Other News for HOOK
Hookipa Pharma (HOOK) Plans Voluntary Nasdaq Delisting | HOOK Stock News
Hookipa Pharma to delist shares from Nasdaq
HOOKIPA Pharma (HOOK) Announces Delisting and Asset Sale Plan
HOOKIPA Pharma to delist from Nasdaq and liquidate following Gilead asset sale
HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock | HOOK ...